Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests
Hiam Chemaitelly, Sarwat Mahmud, Silva P. Kouyoumjian, Zaina Al‐Kanaani, Joumana G. Hermez, Laith J. Abu‐Raddad – 23 January 2019 – Expanding hepatitis C virus (HCV) treatment coverage is challenged by limited testing and diagnosis. This study assessed the risk of exposure, for the Middle East and North Africa, by population, yields of testing, and program efficiency of testing strategies. A standardized and systematically assembled database of 2,542 HCV antibody prevalence studies on 49 million individuals was analyzed.